Fig. 4: Combined SHP2 and MEK inhibition synergistically inhibits EOC PDCs growth.

a Dose-response curves of selumetinib and trametinib alone and in combination with SHP099 (1000 nM, 3000 nM and 10,000 nM) in PDCs (FMOC11, FMOC02_3, FMOC17 and FMOC25_2) and Kuramochi cell line measured with cell viability assay after 1 week. Shown is one representative experiment of at least three replicates. The individual 2D synergy plots for each sample are presented in Supplementary Fig. 7. b Immunoblots for phospho-ERK and total ERK levels in lysates of PDCs and Kuramochi cell line treated with DMSO, selumetinib, trametinib, SHP099 or combinations as indicated. β-tubulin was used as a loading control.